Virtustream Named a Leader in Report Covering Hosted Private Cloud Services Market by Independent Research Firm
25.6.2020 18:38:00 EEST | Business Wire | Press release
Virtustream, an enterprise-class cloud company and Dell Technologies business, shared today that it has been named a leader in The Forrester Wave™: Hosted Private Cloud Services in North America, Q2 2020. The report details Forrester Research’s findings on how well vendors fulfill enterprise customers’ requirements for their hosted private cloud solution.
One of only two vendors to receive the highest score possible in the services and customer experience criterion in the report, Virtustream also received the highest score possible in the criteria for availability SLAs, security capabilities, innovation roadmap and planned enhancements.
The report notes that Virtustream “has clearly succeeded in supporting enterprise resource planning (ERP) with SAP, which still represents the majority of its revenues, and is now doubling down on healthcare with its embrace of Epic…” Additionally, the report states that “Virtustream has never wavered from its ambition to be the cloud partner of choice for mission-critical workloads,” expanding further to state, “Virtustream is a good fit for customers looking to host their most challenging mission-critical packaged applications — especially Epic and SAP – on private, rather than public, cloud platforms.”
Virtustream Enterprise and Healthcare Cloud platforms, combined with its broad portfolio of xStreamCare Services are designed for security, performance, compliance and assured service levels for mission-critical enterprise applications including those from SAP, Microsoft, Oracle and Epic.
“More and more organizations are migrating their mission-critical applications to hosted private cloud platforms as part of their IT transformational journeys,” says Mike Zolla, Vice President, Cloud Platform Engineering and Delivery, Virtustream. “As Forrester notes, our ambition from the beginning was to design a platform purpose-built for mission-critical workloads. Our innovation engine has always been deeply rooted in providing our customers with an amazing experience and meeting their most demanding business needs for modern, secure, agile and high-performing IT solutions.”
For more information on Virtustream go here. Interested parties can download the full report here.
About Virtustream
Virtustream LLC, a Dell Technologies business, is the enterprise-class cloud company that is trusted by organizations worldwide to migrate and run their mission-critical applications in the cloud. For enterprises, service providers, healthcare organizations and government agencies, Virtustream’s xStreamCare professional and managed services, and the xStream® Management Platform and Infrastructure-as-a-Service (IaaS) meet the security, compliance, performance, efficiency, and consumption-based billing requirements of complex production applications in the cloud – whether private, public or hybrid.
Virtustream is a trademark of Virtustream LLC. Other trademarks may be trademarks of their respective owners.
SAP and other SAP products and services mentioned herein as well as their respective logos are trademarks or registered trademarks of SAP SE in Germany and other countries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200625005678/en/
Contact information
For press inquiries:
Visit the Virtustream newsroom
Or contact:
Frank E. Smith
Head of Global Communications, Virtustream
Frank.E.Smith@Virtustream.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mosaic Therapeutics appoints Dr Vince O'Neill, MD, as Head of R&D1.4.2026 12:11:00 EEST | Press release
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company developing next-generation, Synergistic Precision combination therapies, today announced the appointment of Dr Vince O’Neill as Head of Research and Development (R&D) to support its next phase of growth. “We are delighted to welcome Vince to the Mosaic leadership team at this pivotal stage of the company’s evolution,”said Thomas Fuchs, CEO, Mosaic Therapeutics.“His deep expertise in targeted oncology drug development and diagnostics will be instrumental as we advance our pipeline to bring transformative therapies to patients in need.” Vince is a board-certified medical oncologist and highly experienced biotechnology executive, bringing over two decades of therapeutic and diagnostic R&D experience within industry to Mosaic Therapeutics, with a track record spanning from IND through to NDA/BLA/MAA approval. Most recently he served at BioXcel Therapeutics as EVP, Head of Product Developme
The AI Summit London Launches Strategic Partnerships with London Business School and General Purpose to Ignite New Era in AI Leadership1.4.2026 10:00:00 EEST | Press release
The AI Summit London, the conference where commercial AI comes to life, has announced strategic collaborations with London Business School and General Purpose to introduce two dedicated AI Training programmes, taking place ahead of the conference on 9 June. Drawing upon the globally recognised expertise in executive education at the London Business School’s Data Science & AI Initiative (DSAI), the one-day AI Leadership Accelerator is a high-impact session designed to equip senior business leaders with the knowledge and tools to unlock real and profitable value from AI. The DSAI at London Business School helps leaders make sense of AI in a way that goes beyond the hype, focusing on what it really means for their organisations, industries, and competitive positioning. Drawing on rigorous, cross-disciplinary research, DSAI provides clear, evidence-based insights - equipping executives with the perspective needed to make confident, high-stakes decisions. “Through our work we increasingly s
Samsung Research Reveals Over Half of Europeans Admit to Looking at a Stranger's Phone Screen in Public – With Nearly a Quarter Doing so out of Sheer Curiosity1.4.2026 09:00:00 EEST | Press release
As millions of Europeans2 get ready to enjoy the Easter weekend, new research from Samsung finds Europe’s public spaces have become shared screens: 56% of people say they have accidentally looked at a stranger’s phone, citing public transport as the most likely place to notice someone else’s screen (57%). Nearly one in four Europeans2 (24%) admit to looking at someone else’s phone out of curiosity, exposing a stream of private content from personal photos to bank details. Samsung Electronics surveyed 11,000 Europeans2 to support the launch of the Galaxy S26 Ultra, which introduces a built-in Privacy Display. This new hardware-based technology keeps screen content visible only from the front to protect privacy from side angles, without compromising the viewing experience3. The study further reveals a gap between perceived phone privacy and reality: While 48%* feel their own phone use is private when using it in crowded places, 52%** find it easy to view someone else’s screen in public.
RevolKa Reimagines Antibody Engineering with "RevoAb ® "1.4.2026 07:30:00 EEST | Press release
RevolKa Ltd. (RevolKa), a venture-backed biotech company providing an advanced AI protein engineering technology platform, called aiProtein®, is pleased to announce the official global launch of RevoAb®, an innovative and quick online service for antibody sequence optimization to solve challenges in physicochemical properties, especially antibodyyields. RevoAb®:The Next-Gen AI Antibody Design Since December 2023, RevolKa has provided an antibody optimization services utilizing aiProtein®. The newly launched RevoAb® is a quick intuitive online antibody sequence optimization service that integrates RevolKa’s core technology—the "Refined Naturalness Framework Engineering". RevoAb® is designed to generate antibody framework sequences optimized for improved physicochemical properties, especially protein expression levels, without trade-off of affinity. This allows researchers worldwide to experience RevolKa’s high-performance antibody design. Key Advantages of RevoAb® Speed: Multiple optimi
Global Beauty Market Grows 10% as AI and E-commerce Reshape Consumer Buying1.4.2026 04:00:00 EEST | Press release
NielsenIQ (NYSE:NIQ), a global leader in consumer intelligence, today released its State of Beauty 2026 report, showing the global beauty market grew 10% year-on-year, with E-commerce expanding six times faster than in-store sales. The findings highlight a rapid shift to digital-first, AI-influenced commerce across key global markets. As consumer expectations evolve toward convenience, personalization, and seamless digital experiences, beauty brands are under increasing pressure to adapt. From AI-powered product discovery to social commerce and livestream shopping, the path to purchase is becoming more dynamic—requiring brands to move faster and engage consumers across an increasingly complex ecosystem. Key findings from the State of Beauty 2026 report: Global beauty sales grew 10% year-over-year, driven by strong digital acceleration E-commerce is growing 6x faster than in-store sales, reshaping channel strategies 49% of consumers are willing to pay more for locally made products, ref
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
